Skip to main content
Top
Published in: EJNMMI Research 1/2013

Open Access 01-12-2013 | Original research

Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H

Authors: Florian Bretin, Geoffrey Warnock, Mohamed Ali Bahri, Joël Aerts, Nathalie Mestdagh, Tim Buchanan, Anne Valade, Frédéric Mievis, Fabrice Giacomelli, Christian Lemaire, André Luxen, Eric Salmon, Alain Seret, Alain Plenevaux

Published in: EJNMMI Research | Issue 1/2013

Login to get access

Abstract

Background

[18F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic vesicle protein 2A, the binding site for the antiepileptic levetiracetam. The objectives of this study were to evaluate the radiation dosimetry of [18F]UCB-H in a preclinical trial and to determine the maximum injectable dose according to guidelines for human biomedical research. The radiation dosimetry was derived by organ harvesting and dynamic micro positron emission tomography (PET) imaging in mice, and the results of both methods were compared.

Methods

Twenty-four male C57BL-6 mice were injected with 6.96 ± 0.81 MBq of [18F]UCB-H, and the biodistribution was determined by organ harvesting at 2, 5, 10, 30, 60, and 120 min (n = 4 for each time point). Dynamic microPET imaging was performed on five male C57BL-6 mice after the injection of 9.19 ± 3.40 MBq of [18F]UCB-H. A theoretical dynamic bladder model was applied to simulate urinary excretion. Human radiation dose estimates were derived from animal data using the International Commission on Radiological Protection 103 tissue weighting factors.

Results

Based on organ harvesting, the urinary bladder wall, liver and brain received the highest radiation dose with a resulting effective dose of 1.88E-02 mSv/MBq. Based on dynamic imaging an effective dose of 1.86E-02 mSv/MBq was calculated, with the urinary bladder wall and liver (brain was not in the imaging field of view) receiving the highest radiation.

Conclusions

This first preclinical dosimetry study of [18F]UCB-H showed that the tracer meets the standard criteria for radiation exposure in clinical studies. The dose-limiting organ based on US Food and Drug Administration (FDA) and European guidelines was the urinary bladder wall for FDA and the effective dose for Europe with a maximum injectable single dose of approximately 325 MBq was calculated. Although microPET imaging showed significant deviations from organ harvesting, the Pearson’s correlation coefficient between radiation dosimetry derived by either method was 0.9666.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004, 101: 9861. 10.1073/pnas.0308208101PubMedCentralCrossRef Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004, 101: 9861. 10.1073/pnas.0308208101PubMedCentralCrossRef
2.
go back to reference Warnock G, Aerts J, Bahri M, Bretin F, Buchanan T, Klitgaard H: Characterization of a novel radiotracer targeting synaptic vesicle protein 2A (SV2A). World Mol Imag Conf 2012, 134. Warnock G, Aerts J, Bahri M, Bretin F, Buchanan T, Klitgaard H: Characterization of a novel radiotracer targeting synaptic vesicle protein 2A (SV2A). World Mol Imag Conf 2012, 134.
3.
go back to reference Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR: MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999, 40: 37S-61S. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR: MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999, 40: 37S-61S.
4.
go back to reference Bahri MA, Warnock G, Plenevaux A, Choquet P, Constantinesco A, Salmon E, Luxen A, Seret A: Performance evaluation of the General Electric eXplore CT 120 micro-CT using the vmCT phantom. Nucl Instrum Methods Phys Res, Sect. A 2011, 648: S181-S185.CrossRef Bahri MA, Warnock G, Plenevaux A, Choquet P, Constantinesco A, Salmon E, Luxen A, Seret A: Performance evaluation of the General Electric eXplore CT 120 micro-CT using the vmCT phantom. Nucl Instrum Methods Phys Res, Sect. A 2011, 648: S181-S185.CrossRef
5.
go back to reference Feldkamp L, Davis L, Kress J: Practical cone-beam algorithm. JOSA A 1984, 1: 612–619. 10.1364/JOSAA.1.000612CrossRef Feldkamp L, Davis L, Kress J: Practical cone-beam algorithm. JOSA A 1984, 1: 612–619. 10.1364/JOSAA.1.000612CrossRef
6.
go back to reference Laforest R, Longford D, Siegel S, Newport DF, Yap J: Performance evaluation of the microPET® - FOCUS-F120. IEEE Trans Nucl Sci 2007, 54: 42–49.CrossRef Laforest R, Longford D, Siegel S, Newport DF, Yap J: Performance evaluation of the microPET® - FOCUS-F120. IEEE Trans Nucl Sci 2007, 54: 42–49.CrossRef
7.
go back to reference Defrise M, Kinahan P, Townsend DW, Michel C, Sibomana M, Newport D: Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imag 1997, 16: 145–158.CrossRef Defrise M, Kinahan P, Townsend DW, Michel C, Sibomana M, Newport D: Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imag 1997, 16: 145–158.CrossRef
8.
go back to reference Bahri MA, Plenevaux A, Warnock G, Luxen A, Seret A: NEMA NU4–2008 image quality performance report for the microPET Focus 120 and for various transmission and reconstruction methods. J Nucl Med 2009, 50: 1730–1738. 10.2967/jnumed.109.063974CrossRef Bahri MA, Plenevaux A, Warnock G, Luxen A, Seret A: NEMA NU4–2008 image quality performance report for the microPET Focus 120 and for various transmission and reconstruction methods. J Nucl Med 2009, 50: 1730–1738. 10.2967/jnumed.109.063974CrossRef
9.
go back to reference Kirshner A, Ice R, Beierwaltes W: Radiation dosimetry of 19-iodocholesterol [I31I]: the pitfalls of using tissue concentration data (reply). J Nucl Med 1975, 16: 248–249. Kirshner A, Ice R, Beierwaltes W: Radiation dosimetry of 19-iodocholesterol [I31I]: the pitfalls of using tissue concentration data (reply). J Nucl Med 1975, 16: 248–249.
10.
go back to reference Stabin MG, Sparks RB, Crowe E: OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46: 1023–1027. Stabin MG, Sparks RB, Crowe E: OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46: 1023–1027.
11.
go back to reference Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG: Dose to the fetus from radionuclides in the bladder. Health Phys 1973, 25: 147. 10.1097/00004032-197308000-00009CrossRef Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG: Dose to the fetus from radionuclides in the bladder. Health Phys 1973, 25: 147. 10.1097/00004032-197308000-00009CrossRef
12.
go back to reference Stabin MG: Fundamentals of Nuclear Medicine Dosimetry. New York: Springer; 2008. Stabin MG: Fundamentals of Nuclear Medicine Dosimetry. New York: Springer; 2008.
13.
go back to reference Valentin J: Icrp: The 2007 Recommendations of the International Commission on Radiological Protection. : Elsevier Health Sciences; 2008. Valentin J: Icrp: The 2007 Recommendations of the International Commission on Radiological Protection. : Elsevier Health Sciences; 2008.
14.
go back to reference Protection ICoR: 1990 Adopted by the Commission in November 1990. Recommendations of the International Commission Radiological Protection 1991, 60. Protection ICoR: 1990 Adopted by the Commission in November 1990. Recommendations of the International Commission Radiological Protection 1991, 60.
15.
go back to reference Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DHS: Radiation dose estimates for [18 F] 5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol 2008, 10: 341–348. 10.1007/s11307-008-0160-5CrossRef Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DHS: Radiation dose estimates for [18 F] 5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol 2008, 10: 341–348. 10.1007/s11307-008-0160-5CrossRef
16.
go back to reference Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA: 18F-fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 2003, 44: 1482–1488. Vesselle H, Grierson J, Peterson LM, Muzi M, Mankoff DA, Krohn KA: 18F-fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 2003, 44: 1482–1488.
17.
go back to reference Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM, Krohn KA: [18F] fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001, 42: 679–684. Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM, Krohn KA: [18F] fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001, 42: 679–684.
18.
go back to reference Rousset OG, Ma Y, Evans AC: Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998, 39: 904–911. Rousset OG, Ma Y, Evans AC: Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998, 39: 904–911.
19.
go back to reference Yang Y, Rendig S, Siegel S, Newport DF, Cherry SR: Cardiac PET imaging in mice with simultaneous cardiac and respiratory gating. Phys Med Biol 2005, 50: 2979. 10.1088/0031-9155/50/13/001CrossRef Yang Y, Rendig S, Siegel S, Newport DF, Cherry SR: Cardiac PET imaging in mice with simultaneous cardiac and respiratory gating. Phys Med Biol 2005, 50: 2979. 10.1088/0031-9155/50/13/001CrossRef
20.
go back to reference Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, Itoh M, Miyake M, Watanuki S: Estimation of absorbed dose for 2-[F-18] fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 1998, 25: 565–574. 10.1007/s002590050257CrossRef Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, Itoh M, Miyake M, Watanuki S: Estimation of absorbed dose for 2-[F-18] fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 1998, 25: 565–574. 10.1007/s002590050257CrossRef
21.
go back to reference Verbruggen A, Coenen HH, Deverre JR, Guilloteau D, Langstrom B, Salvadori PA, Halldin C: Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 2008, 35: 2144–2151. 10.1007/s00259-008-0853-7CrossRef Verbruggen A, Coenen HH, Deverre JR, Guilloteau D, Langstrom B, Salvadori PA, Halldin C: Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 2008, 35: 2144–2151. 10.1007/s00259-008-0853-7CrossRef
23.
go back to reference Carson RE, Herscovitch P, Daube-Witherspoon ME: Quantitative Functional Brain Imaging with Positron Emission Tomography. Amsterdam: Elsevier Science; 1998. Carson RE, Herscovitch P, Daube-Witherspoon ME: Quantitative Functional Brain Imaging with Positron Emission Tomography. Amsterdam: Elsevier Science; 1998.
Metadata
Title
Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H
Authors
Florian Bretin
Geoffrey Warnock
Mohamed Ali Bahri
Joël Aerts
Nathalie Mestdagh
Tim Buchanan
Anne Valade
Frédéric Mievis
Fabrice Giacomelli
Christian Lemaire
André Luxen
Eric Salmon
Alain Seret
Alain Plenevaux
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2013
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/2191-219X-3-35

Other articles of this Issue 1/2013

EJNMMI Research 1/2013 Go to the issue